Pluri (PLUR) Retained Earnings (2011 - 2025)
Pluri (PLUR) posted quarterly Retained Earnings of -$455.4 million for Q4 2025, down 6.09% year-over-year from -$485.0 million in Q4 2024, and down 1.46% quarter-over-quarter from -$448.9 million in Q3 2025.
Pluri (PLUR) Retained Earnings (2011 - 2025) Analysis & Trends
Pluri (PLUR) has reported Retained Earnings for 15 consecutive years, with -$455.4 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Retained Earnings fell 6.09% year-over-year to -$455.4 million; the TTM figure through Dec 2025 stood at -$455.4 million (down 6.09% YoY), while the FY2025 annual figure was -$443.1 million, down 5.37% from the prior year.
- Retained Earnings eased to -$455.4 million in Q4 2025 per PLUR's latest filing, from -$448.9 million in the prior quarter.
- Across five years, Retained Earnings topped out at $431.0 million in Q1 2025 and bottomed at -$455.4 million in Q4 2025.
- Historically, Retained Earnings has averaged -$154.6 million across 5 years, with a median of -$369.8 million in 2022.
- On a YoY basis, Retained Earnings climbed as much as 230.22% in 2021 and fell as far as 210.23% in 2021.
- Pluri's Retained Earnings stood at $392.2 million in 2021, then grew by 4.2% to $408.7 million in 2022, then tumbled by 200.19% to -$409.4 million in 2023, then decreased by 4.85% to -$429.3 million in 2024, then retreated by 6.09% to -$455.4 million in 2025.
- Business Quant data shows PLUR's Retained Earnings at -$455.4 million in Q4 2025, -$448.9 million in Q3 2025, and -$443.1 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Pluri | 16.21 Mn | 3.72 Mn | 86,000.00 | -455.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -455.45 Mn |
| Sep 30, 2025 | -448.91 Mn |
| Jun 30, 2025 | -443.06 Mn |
| Mar 31, 2025 | 430.98 Mn |
| Dec 31, 2024 | -429.31 Mn |
| Sep 30, 2024 | -426.35 Mn |
| Jun 30, 2024 | -420.47 Mn |
| Mar 31, 2024 | 414.39 Mn |
| Dec 31, 2023 | -409.45 Mn |
| Sep 30, 2023 | 413.45 Mn |
| Jun 30, 2023 | -399.58 Mn |
| Mar 31, 2023 | -393.13 Mn |
| Dec 31, 2022 | 408.69 Mn |
| Sep 30, 2022 | -377.38 Mn |
| Jun 30, 2022 | 401.30 Mn |
| Mar 31, 2022 | -362.26 Mn |
| Dec 31, 2021 | 392.23 Mn |
| Sep 30, 2021 | -341.45 Mn |
| Jun 30, 2021 | -330.02 Mn |
| Mar 31, 2021 | -315.45 Mn |